GSK2890457 Phase 2 trial evaluates safety, tolerability, and pharmacodynamics in Type 2 Diabetes.

Type 2 Diabetes (T2D) is a chronic metabolic disorder characterized by insulin resistance and pancreatic beta-cell dysfunction, leading to hyperglycemia. Current treatments often involve metformin, sulfonylureas, or GLP-1 receptor agonists like liraglutide, which improve glycemic control but may have limitations in efficacy, side effects, or administration routes. There's a continuous need for novel therapeutic agents that offer improved safety profiles, enhanced efficacy, or alternative mechanisms of action to address the complex pathophysiology of T2D and its associated comorbidities like obesity. GSK2890457 represents a new investigational compound aiming to fill this therapeutic gap.

This was a double-blind, randomized, placebo-controlled, staggered-parallel Phase 2 study (NCT01725126) enrolling 53 participants, including healthy volunteers and subjects with Type 2 Diabetes and obesity. The study comprised three parts: Part A evaluated single doses of GSK2890457 orally on Day 1 and Day 42 in healthy subjects. Part B assessed GSK2890457 in combination with liraglutide (up to 1.8 mg subcutaneous injection daily) over a 6-week treatment period in T2D subjects. Part C investigated GSK2890457 combined with metformin (usual dose) over 6 weeks in T2D subjects. Primary endpoints included safety, tolerability, and pharmacodynamics.